Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses

It is uncertain whether the risk of vertebral fracture (VF) and multiple vertebral fractures (MVFs; ≥2 VFs) after denosumab (DMAb) discontinuation is related to treatment duration. A prior analysis of Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) and FREEDOM Ext...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosman, Felicia, Huang, Shuang, McDermott, Michele, Cummings, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092421/
https://www.ncbi.nlm.nih.gov/pubmed/36088628
http://dx.doi.org/10.1002/jbmr.4705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092421/
https://www.ncbi.nlm.nih.gov/pubmed/36088628
http://dx.doi.org/10.1002/jbmr.4705

Ejemplares similares